BRISTOL-MYERS ZERIT TRIAL SHOWS EQUIVALENCE TO AZT IN AZT-EXPERIENCED PATIENTS: ADVISORY COMMITTEE RECOMMENDS NARROW INDICATION, TRADITIONAL APPROVAL
Executive Summary
Bristol-Myers Squibb's Zerit should receive traditional approval from FDA with an indication for patients with prior AZT use, FDA's Antiviral Drugs Advisory Committee voted 4-3 at a Nov. 8 meeting in Silver Spring, Md.